KOD Kodiak Sciences Inc

61.6
+0.02  (+0%)
Previous Close 61.58
Open 61.81
Price To Book 8.36
Market Cap 2,740,244,892
Shares 44,484,495
Volume 240,978
Short Ratio
Av. Daily Volume 335,062
Stock charts supplied by TradingView

NewsSee all news

  1. Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

    PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  2. Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

    PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  3. Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020

    PALO ALTO, Calif., May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  4. Kodiak Sciences Appoints Charles Bancroft to Board of Directors

    PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  5. "Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use

    PALO ALTO, Calif., March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 pivotal trial commencement of dosing announced October 10, 2019 with interim data 2020 and final data 2021.
KSI-301
Wet age-related macular degeneration (AMD)
Phase 3 pivotal trial to commence September/October 2020.
KSI-301
Diabetic macular edema (DME)
Phase 3 trial to be initiated in September/October 2020.
KSI-301
Retinal vein occlusion (RVO)
Phase 3 trial to be initiated.
KSI-301
Diabetic retinopathy

Latest News

  1. Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference

    PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  2. Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights

    PALO ALTO, Calif., May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  3. Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020

    PALO ALTO, Calif., May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  4. Kodiak Sciences Appoints Charles Bancroft to Board of Directors

    PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  5. "Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use

    PALO ALTO, Calif., March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  6. Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  7. Kodiak Sciences to Present at Upcoming Conferences

    PALO ALTO, Calif., Feb. 27, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  8. Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and Degeneration 2020 Meeting

    PALO ALTO, Calif., Feb. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  9. Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting

    PALO ALTO, Calif., Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  10. Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

    PALO ALTO, Calif., Jan. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  11. Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors

    PALO ALTO, Calif., Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  12. Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    PALO ALTO, Calif., Dec. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  13. Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock

    PALO ALTO, Calif., Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  14. Kodiak Sciences Announces Proposed Offering of Common Stock

    PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  15. Kodiak Sciences to Present at the Evercore ISI HealthCONx Conference

    PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  16. Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

    PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to

  17. Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  18. Kodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019

    PALO ALTO, Calif., Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  19. Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecialty Day

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  20. Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301

    PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301.

  21. Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration

    PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases,

  22. Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

    PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  23. Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  24. Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting

    PALO ALTO, Calif., Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  25. Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference

    PALO ALTO, Calif., Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today

  26. Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

    PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today